- Twist Bioscience press release ( NASDAQ: TWST ): Q1 GAAP EPS of -$0.74 beats by $0.36 .
- Revenue of $54.24M (+29.1% Y/Y) misses by $0.23M .
- Q2 Outlook : Revenue is expected to be approximately $56.5M vs. consensus of $61.83M; Gross margin is expected to be 30%.
- FY2023 Outlook : Revenue guidance is unchanged from the November 2022 guidance and is expected to be in the range of $261M to $269M vs. consensus of $265.57M;Gross margin is expected to be approximately 39%-40%; Operating loss is expected to be approximately $225M.
For further details see:
Twist Bioscience GAAP EPS of -$0.74 beats by $0.36, revenue of $54.24M misses by $0.23M